Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05227703 · ClinicalTrials.gov registry record · Phase 2
A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia
A Phase 2 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 2
- Development phase
- 391
- Enrollment target
NCT05227703 is a Phase 2 study that has completed, run by AbbVie. The registered enrollment target is 391 participants.
The verdict
NCT05227703, a Phase 2 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 391 participants
- Enrollment target
Study Summary
This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in male and female adult participants who have schizophrenia and are experiencing an acute exacerbation of psychosis.
Interventions
- DRUG Placebo
- DRUG Emraclidine 30 mg
- DRUG Emraclidine 15 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 391 participants |
| Start Date | 2022-07-05 |
| Est. Completion | 2024-09-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05227703
The ClinicalTrials.gov registry entry for NCT05227703 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 391 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05227703 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05227703 about?
NCT05227703 is a clinical study titled "A Trial of 15 and 30 mg Doses of CVL-231 (Emraclidine) in Participants With Schizophrenia". This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, 6-week trial to evaluate the efficacy, safety, and tolerability of 2 fixed doses of CVL-231 (Emraclidine) (15 mg QD and 30 mg QD) in male and female adult participants who have schizophrenia and are experie...
What is the current status of trial NCT05227703?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 391 participants. The study started on 2022-07-05. Estimated completion is 2024-09-11.
What interventions are being tested in trial NCT05227703?
The interventions under investigation include: Placebo (DRUG), Emraclidine 30 mg (DRUG), Emraclidine 15 mg (DRUG).
Who is sponsoring clinical trial NCT05227703?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.